

NeuroRx Expanded Access Protocol RLF-100-EA-1 V1.0

Jonathan C. Javitt, MD, MPH¹

¹Johns Hopkins University

July 25, 2020

Abstract

RLF-100 (aviptadil) is a synthetic form of Vasoactive Intestinal Polypeptide (VIP), a ubiquitous, naturally synthesized human peptide with extensively documented antiinflammatory, anti-cytokine cascade properties. It has been granted FDA Fast Track Designation for treatment of Critical COVID-19 with Respiratory Failure. A phase 2/3 trial is underway that has passed its first evaluation at 30 patients for safety and futility. This expanded access protocol is designed to offer access to investigational use of RLF-100 to patients who do not qualify for inclusion in Protocol RLF-100-001 (NCT04311697) either on the basis of specific medical exclusions or because there is no accessible study site available to the prospective participant.

Hosted file

NeuroRx Expanded Access Protocol RLF-100-EA-1 V1.0.pdf available at <https://authorea.com/users/321659/articles/472197-neurorx-expanded-access-protocol-rlf-100-ea-1-v1-0>